Inactive Instrument

News Prosensa Holding NV

Equities

NL0010524443

End-of-day quote Nasdaq Other stock markets
- ^USD	-

2014	BioMarin Pharmaceutical : S&P 500 ticks up to record on central bank bets	RE
2014	BioMarin Pharmaceutical : to buy Prosensa in $840 million deal	RE

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Prosensa Announces Intent to Voluntarily Delist From NASDAQ	15-01-30	GL
Prosensa Announces Shareholder Approval of Certain Matters Relating to the BioMarin Tender Offer	15-01-13	GL
Prosensa NV : BioMarin and Prosensa Announce Expiration of the Hart-Scott-Rodino Waiting Period for BioMarin's Proposed Acquisition of Prosensa	14-12-27	PU
BioMarin Pharmaceutical : S&P 500 ticks up to record on central bank bets	14-11-24	RE
BioMarin Pharmaceutical : to buy Prosensa in $840 million deal	14-11-24	RE
Prosensa NV : Cure Duchenne and Prosensa to Present Collaboration at Partnering for Cures Conference	14-11-12	BU
Prosensa NV : start indiening registratiedossier bij FDA voor Duchenne-medicijn drisapersen	14-10-13	PU
Prosensa extends the re-dosing of drisapersen in Europe in patients with Duchenne muscular dystrophy	14-09-26	GL
Prosensa NV : -resultaten tweede kwartaal 2014 en recente ontwikkelingen	14-08-13	PU
Prosensa NV : to Present at the Wedbush 2014 Life Sciences Conference	14-08-06	PU
Prosensa NV : versterkt Management Team en Raad van Commissarissen	14-06-30	PU
Prosensa Awarded $200,000 Research Grant from PPMD	14-06-27	GL
Prosensa NV : voltooit rekrutering patiënten in natuurlijke beloopstudie	14-06-27	PU
Prosensa NV : kondigt registratieroute aan voor drisapersen als mogelijk medicijn tegen spierziekte Duchenne	14-06-06	PU
Prosensa to Present at the Jefferies 2014 Global Healthcare Conference	14-05-28	GL
Prosensa NV : jaarresultaten 2013 en recente ontwikkelingen	14-03-18	PU
Prosensa Reports Initial Findings from the Further Clinical Data Analyses of Drisapersen for the Treatment of Duchenne Muscular Dystrophy	14-01-16	GL
Prosensa Holding NV : Prosensa Comments on Drisapersen Program Update	13-12-19	PU
Prosensa Holding NV : Investment risks of fast-tracking biotech drugs become apparent	13-12-18	RE
Prosensa Holding NV : Prosensa Announces Extraordinary Shareholders Meeting to Appoint Dr. Georges Gemayel	13-12-10	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Prosensa Holding NV

Equities

NL0010524443

Summary

Filters